Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Verve Therapeutics, Inc. (VERV) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Verve Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1840574.
Total stock buying since 2021: $65,955,047.
Total stock sales since 2021: $45,828,770.
Total stock option exercises since 2021: $876,904.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 24,054 | $99,822 | 78,720 | $0 |
| 2024 | 76,000 | $475,760 | 555 | $3,130 | 31,875 | $86,100 |
| 2023 | 1,800,000 | $18,000,000 | 554 | $6,343 | 1,875 | $0 |
| 2022 | 14,000 | $207,066 | 1,249,210 | $38,670,433 | 313,419 | $542,462 |
| 2021 | 2,482,200 | $47,272,221 | 177,693 | $7,049,042 | 177,693 | $248,342 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-04 | 0 | $0 | 24,054 | $99,822 | 78,720 | $0 |
| 2024-12 | 0 | $0 | 555 | $3,130 | 0 | $0 |
| 2024-11 | 0 | $0 | 0 | $0 | 1,875 | $0 |
| 2024-06 | 0 | $0 | 0 | $0 | 30,000 | $86,100 |
| 2024-05 | 76,000 | $475,760 | 0 | $0 | 0 | $0 |
| 2023-12 | 1,800,000 | $18,000,000 | 0 | $0 | 0 | $0 |
| 2023-11 | 0 | $0 | 554 | $6,343 | 1,875 | $0 |
| 2022-11 | 0 | $0 | 379,686 | $13,194,761 | 1,875 | $0 |
| 2022-10 | 0 | $0 | 211,089 | $8,050,950 | 50,000 | $69,500 |
| 2022-09 | 0 | $0 | 60,000 | $2,124,000 | 60,000 | $88,800 |
| 2022-08 | 0 | $0 | 50,000 | $1,495,000 | 50,000 | $69,500 |
| 2022-07 | 0 | $0 | 281,775 | $6,473,846 | 80,000 | $112,099 |
| 2022-06 | 0 | $0 | 53,219 | $821,159 | 0 | $0 |
| 2022-05 | 10,000 | $121,530 | 0 | $0 | 0 | $0 |
| 2022-03 | 4,000 | $85,536 | 3,971 | $115,198 | 69,674 | $199,964 |
| 2022-02 | 0 | $0 | 48,764 | $1,421,645 | 0 | $0 |
| 2022-01 | 0 | $0 | 160,706 | $4,973,874 | 1,870 | $2,599 |
| 2021-12 | 8,700 | $275,721 | 177,693 | $7,049,042 | 177,693 | $248,342 |
| 2021-06 | 2,473,500 | $46,996,500 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-02 | Politi Jason (Chief Technical Ops. Off.) | Sale | 3,235 | 4.15 | 13,425 |
| 2025-04-02 | Lister Troy (Chief Scientific Officer) | Sale | 2,189 | 4.15 | 9,084 |
| 2025-04-02 | Nickerson Joan (Chief Administrative Officer) | Sale | 2,777 | 4.15 | 11,524 |
| 2025-04-02 | Kathiresan Sekar (Chief Executive Officer) | Sale | 9,822 | 4.15 | 40,761 |
| 2025-04-02 | Dorval Allison (Chief Financial Officer) | Sale | 3,350 | 4.15 | 13,902 |
| 2025-04-02 | Ashe Andrew D. (See Remarks) | Sale | 2,681 | 4.15 | 11,126 |
| 2025-04-01 | Politi Jason (Chief Technical Ops. Off.) | Option Ex | 8,815 | .00 | 0 |
| 2025-04-01 | Lister Troy (Chief Scientific Officer) | Option Ex | 7,340 | .00 | 0 |
| 2025-04-01 | Nickerson Joan (Chief Administrative Officer) | Option Ex | 9,315 | .00 | 0 |
| 2025-04-01 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 33,000 | .00 | 0 |
| 2025-04-01 | Dorval Allison (Chief Financial Officer) | Option Ex | 11,250 | .00 | 0 |
| 2025-04-01 | Ashe Andrew D. (See Remarks) | Option Ex | 9,000 | .00 | 0 |
| 2024-12-02 | Dorval Allison (Chief Financial Officer) | Sale | 555 | 5.64 | 3,130 |
| 2024-11-29 | Dorval Allison (Chief Financial Officer) | Option Ex | 1,875 | .00 | 0 |
| 2024-06-28 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 30,000 | 2.87 | 86,100 |
| 2024-05-14 | Ashe Andrew D. (See Remarks) | Buy | 76,000 | 6.26 | 475,760 |
| 2023-12-01 | Yeshwant Krishna | Buy | 1,800,000 | 10.00 | 18,000,000 |
| 2023-11-29 | Dorval Allison (Chief Financial Officer) | Sale | 554 | 11.45 | 6,343 |
| 2023-11-29 | Dorval Allison (Chief Financial Officer) | Option Ex | 1,875 | .00 | 0 |
| 2022-11-29 | Dorval Allison (Chief Financial Officer) | Sale | 554 | 22.10 | 12,243 |
| 2022-11-29 | Dorval Allison (Chief Financial Officer) | Option Ex | 1,875 | .00 | 0 |
| 2022-11-04 | Yeshwant Krishna (Director) | Sale | 48,583 | 32.00 | 1,554,801 |
| 2022-11-03 | Alphabet Inc. (Other) | Sale | 99,137 | 33.10 | 3,281,137 |
| 2022-11-03 | Yeshwant Krishna (Director) | Sale | 49,568 | 33.10 | 1,640,552 |
| 2022-11-02 | Alphabet Inc. (Other) | Sale | 57,303 | 35.94 | 2,059,641 |
| 2022-11-02 | Yeshwant Krishna (Director) | Sale | 28,652 | 35.94 | 1,029,838 |
| 2022-11-01 | Alphabet Inc. (Other) | Sale | 63,926 | 37.72 | 2,411,033 |
| 2022-11-01 | Yeshwant Krishna (Director) | Sale | 31,963 | 37.72 | 1,205,516 |
| 2022-10-31 | Alphabet Inc. (Other) | Sale | 107,393 | 39.41 | 4,232,680 |
| 2022-10-31 | Yeshwant Krishna (Director) | Sale | 53,696 | 39.41 | 2,116,320 |
| 2022-10-03 | Kathiresan Sekar (Chief Executive Officer) | Sale | 50,000 | 34.04 | 1,701,950 |
| 2022-10-03 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 50,000 | 1.39 | 69,500 |
| 2022-09-23 | Bellinger Andrew (CSO & CMO) | Sale | 60,000 | 35.40 | 2,124,000 |
| 2022-09-23 | Bellinger Andrew (CSO & CMO) | Option Ex | 60,000 | 1.48 | 88,800 |
| 2022-08-10 | Kathiresan Sekar (Chief Executive Officer) | Sale | 50,000 | 29.90 | 1,495,000 |
| 2022-08-10 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 50,000 | 1.39 | 69,500 |
| 2022-07-20 | Bellinger Andrew (CSO & CMO) | Sale | 20,000 | 34.90 | 698,000 |
| 2022-07-20 | Bellinger Andrew (CSO & CMO) | Option Ex | 20,000 | 1.39 | 27,799 |
| 2022-07-19 | Kathiresan Sekar (Chief Executive Officer) | Sale | 50,000 | 29.90 | 1,495,000 |
| 2022-07-19 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 50,000 | 1.39 | 69,500 |
| 2022-07-13 | Bellinger Andrew (CSO & CMO) | Sale | 10,000 | 24.90 | 249,000 |
| 2022-07-13 | Bellinger Andrew (CSO & CMO) | Option Ex | 10,000 | 1.48 | 14,800 |
| 2022-07-12 | Fmr Llc (Other) | Sale | 163,000 | 21.01 | 3,424,630 |
| 2022-07-01 | Fmr Llc (Other) | Sale | 38,775 | 15.66 | 607,216 |
| 2022-06-30 | Fmr Llc (Other) | Sale | 18,810 | 15.21 | 286,100 |
| 2022-06-29 | Fmr Llc (Other) | Sale | 34,409 | 15.55 | 535,059 |
| 2022-05-12 | Adelman Burt A (Director) | Buy | 10,000 | 12.15 | 121,530 |
| 2022-03-18 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 69,674 | 2.87 | 199,964 |
| 2022-03-15 | Adelman Burt A (Director) | Buy | 4,000 | 21.38 | 85,536 |
| 2022-03-09 | Fmr Llc (Other) | Sale | 3,971 | 29.01 | 115,198 |
| 2022-02-09 | Fmr Llc (Other) | Sale | 13,190 | 29.46 | 388,577 |
| 2022-02-01 | Fmr Llc (Other) | Sale | 35,574 | 29.04 | 1,033,068 |
| 2022-01-27 | Fmr Llc (Other) | Sale | 8,983 | 29.64 | 266,256 |
| 2022-01-26 | Fmr Llc (Other) | Sale | 149,853 | 30.92 | 4,633,005 |
| 2022-01-04 | Kathiresan Sekar (Chief Executive Officer) | Sale | 1,870 | 39.90 | 74,613 |
| 2022-01-04 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 1,870 | 1.39 | 2,599 |
| 2021-12-28 | Kathiresan Sekar (Chief Executive Officer) | Sale | 6,693 | 39.90 | 267,050 |
| 2021-12-28 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 6,693 | 1.39 | 9,303 |
| 2021-12-27 | Kathiresan Sekar (Chief Executive Officer) | Sale | 42,000 | 41.16 | 1,728,678 |
| 2021-12-27 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 42,000 | 1.39 | 58,379 |
| 2021-12-23 | Kathiresan Sekar (Chief Executive Officer) | Sale | 57,000 | 39.90 | 2,274,300 |
| 2021-12-23 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 57,000 | 1.39 | 79,230 |
| 2021-12-22 | Bellinger Andrew (Chief Scientific Officer) | Sale | 15,000 | 38.47 | 576,990 |
| 2021-12-22 | Bellinger Andrew (Chief Scientific Officer) | Option Ex | 15,000 | 1.48 | 22,200 |
| 2021-12-22 | Kathiresan Sekar (Chief Executive Officer) | Sale | 57,000 | 38.63 | 2,202,024 |
| 2021-12-22 | Kathiresan Sekar (Chief Executive Officer) | Option Ex | 57,000 | 1.39 | 79,230 |
| 2021-12-02 | Ashe Andrew D. (See Remarks) | Buy | 4,000 | 32.10 | 128,419 |
| 2021-12-02 | Adelman Burt A (Director) | Buy | 4,700 | 31.34 | 147,302 |
| 2021-06-21 | Beaudoin Margaret (Vice President, Finance) | Buy | 1,000 | 19.00 | 19,000 |
| 2021-06-21 | Bellinger Andrew (Chief Scientific Officer) | Buy | 5,000 | 19.00 | 95,000 |
| 2021-06-21 | Kathiresan Sekar (Chief Executive Officer) | Buy | 2,500 | 19.00 | 47,500 |
| 2021-06-21 | Cormorant Private Healthcare Fund Iii Lp | Buy | 275,000 | 19.00 | 5,225,000 |
| 2021-06-21 | Logos Global Management Lp (10% Owner) | Buy | 370,000 | 19.00 | 7,030,000 |
| 2021-06-21 | Rock Springs Capital Llc (10% Owner) | Buy | 370,000 | 19.00 | 7,030,000 |
| 2021-06-21 | Casdin Partners Master Fund, L.p. (10% Owner) | Buy | 1,100,000 | 19.00 | 20,900,000 |
| 2021-06-21 | Novo Holdings A/s (10% Owner) | Buy | 350,000 | 19.00 | 6,650,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of VERV listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Verve Therapeutics, Inc. (symbol VERV, CIK number 1840574) see the Securities and Exchange Commission (SEC) website.